
    
      This is a first-in-human, first-in-class, escalating dose trial of an antibody that inhibits
      an anti-apoptotic signal in human macrophages. The major aims of the study are to define the
      safety profile of this new drug, and to determine a recommended dose and schedule for
      potential additional trials.
    
  